Key Highlights

  • Merger issuance includes 814,375 common shares and 179,693 Series A preferred shares to former Aptomer holders.
  • DiamiR shareholders receive 1,979,216 new common shares under a conversion ratio of 0.4102.
  • A 10‑for‑1 reverse split reduces Class A ordinary shares from 6,346,823 to 634,682, aligning the capital base to $100 million authorized.
  • The newly listed common stock carries CUSIP 653942 102 and trades on Nasdaq under the ticker “NIKI”.

Niki BioSolutions completed its merger with DiamiR on July 20, 2026, converting existing equity into a unified capital structure. The deal provided 814,375 newly issued common shares and 179,693 Series A preferred shares to former Aptomer investors, while DiamiR shareholders were allocated 1,979,216 common shares based on a conversion ratio of 0.4102. This equity infusion expands the issued share count and positions the company for future financing activities.

The combined share pool will influence liquidity and market depth as trading begins under the new ticker.

Merger Completion

The merger agreement, first announced on July 14, 2025, required shareholder approval and satisfaction of customary closing conditions. After the domestic incorporation in Delaware, Aptomer re‑incorporated as Niki BioSolutions and the merger subsidiary merged into DiamiR, leaving DiamiR as the surviving entity wholly owned by Niki. The restructuring also introduced a shareholder‑approved incentive plan aimed at talent retention.

By closing the transaction, the company secures a broader asset base and a unified operational platform, setting the stage for integrated research and development pipelines and potential revenue synergies in the biotechnology arena.

Share Structure Realignment

Alongside the merger, a reverse split compressed the share count tenfold, converting each group of ten Class A ordinary shares into one share with a par value of $0.0001. The authorized capital now totals $100 million, divided into 999,999,600 ordinary shares of $0.0001 par value and 400,000 preferred shares. This reduction improves per‑share pricing, meets Nasdaq listing thresholds, and may attract institutional investors seeking higher share prices.

The tighter capital structure also eases dilution pressure from any future issuances.

Capital Base and Governance

The newly formed corporation retains authority to issue up to 160,000,000 shares, comprising 10,000,000 preferred shares and 150,000,000 common shares, each with a par value of $0.0001. The Series A preferred stock is authorized for up to 1,810,000 shares, each carrying the same par value. The corporate bylaws provide directors with flexibility to adjust governance arrangements, while shareholder rights remain protected through established voting thresholds.

The CUSIP 653942 102 now identifies the common stock on Nasdaq, delivering clear market identification. Strengthened governance and transparent share classification should aid analysts monitoring the firm’s performance in the competitive biotech sector.

Upcoming Catalyst

All licensing and management agreements tied to the merger automatically terminated at closing, but a related licensing arrangement specifies a final termination date of July 31, 2026. The expiration of this agreement will trigger the final settlement of any outstanding royalty obligations and could influence cash flow in the short term. Investors should monitor the July 31 deadline for any post‑merger financial adjustments that may affect earnings guidance, especially as the company seeks to advance its pipeline of RNA‑based therapeutics.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.